Variant · Snv

TP53 G245S

CI-VAR-00001676Explore in graph →NP_000537.3:p.Gly245SerNM_000546.5:c.733G>AClinVar 12365 CIViC 879 rs28934575

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
TP53 R273C OR TP53 G245S OR TP53 R213*	Pazopanib + VorinostatCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID12732 In the phase I study of pazopanib and vorinostat in 36 patients with advanced solid tumors, detection of hotspot TP53 mutation was associated with a higher rate of SD ≥6 months/PR, longer median PFS (… (full text at CIViC) PMID 25669829 · Fu et al., 2015 · Open in CIViC	civic
Malignant Neoplasm1
TP53 G245S	MDM2 Inhibitor AMGMDS3	Predictive	D	Supports Resistance	4	accepted	EID4883 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12365	Pathogenic	reviewed by expert panel	3	Li-fraumeni-like syndrome; Li-Fraumeni syndrome 1; Hereditary cancer-predisposing syndrome; Adenocarcinoma; Li-Fraumeni syndrome; Astrocytoma, anaplastic; Atypical teratoid rhabdoid tumor; Ovarian neoplasm; Familial ovarian cancer; Breast carcinoma; Colorectal cancer; Gastric cancer; Malignant tumor of urinary bladder; Adrenocortical carcinoma, hereditary; TP53-related disorder; Medulloblastoma WNT activated; Rhabdomyosarcoma; IDH-wildtype glioblastoma; Neoplasm

Unmapped disease5unmapped disease
TP53 G245S	(functional)	Functional	D	Supports Loss Of Function	3	submitted	EID7108 A reporter assay in FASAY yeast strain using the ADE2 gene under control of the p-21 or RGC p53 response elements was performed to assay p53 hotspot mutation G245S transcriptional activity, with colon… (full text at CIViC) PMID 27589690 · Billant et al., 2016 · Open in CIViC	civic
TP53 G245S	(functional)	Functional	D	Supports Dominant Negative	3	accepted	EID7114 A reporter assay in FASAY yeast strain using the ADE2 gene under control of a p53 response element was performed, with colony color (white vs red) as readout for p53 transactivation activity, where wt… (full text at CIViC) PMID 27589690 · Billant et al., 2016 · Open in CIViC	civic
TP53 G245S	(functional)	Functional	D	Supports Loss Of Function	2	submitted	EID9456 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
TP53 G245S	(functional)	Functional	D	Supports Dominant Negative	3	accepted	EID10253 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic
TP53 G245S	(functional)	Functional	D	Supports Dominant Negative	3	accepted	EID10532 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant G245S originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactiv… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic

Unmapped disease5unmapped disease

TP53 G245S

(functional)

Functional

Supports Loss Of Function

submitted

EID7108

A reporter assay in FASAY yeast strain using the ADE2 gene under control of the p-21 or RGC p53 response elements was performed to assay p53 hotspot mutation G245S transcriptional activity, with colon… (full text at CIViC)

PMID 27589690 · Billant et al., 2016 · Open in CIViC

civic

TP53 G245S

(functional)

Functional

Supports Dominant Negative

accepted

EID7114

A reporter assay in FASAY yeast strain using the ADE2 gene under control of a p53 response element was performed, with colony color (white vs red) as readout for p53 transactivation activity, where wt… (full text at CIViC)

PMID 27589690 · Billant et al., 2016 · Open in CIViC

civic

TP53 G245S

(functional)

Functional

Supports Loss Of Function

submitted

EID9456

Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC)

PMID 20407015 · Jordan et al., 2010 · Open in CIViC

civic

TP53 G245S

(functional)

Functional

Supports Dominant Negative

accepted

EID10253

A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC)

PMID 11896595 · Monti et al., 2002 · Open in CIViC

civic

TP53 G245S

(functional)

Functional

Supports Dominant Negative

accepted

EID10532

Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant G245S originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactiv… (full text at CIViC)

PMID 10519380 · Marutani et al., 1999 · Open in CIViC

civic